Navigation Links
Fewer headaches on the horizon thanks to latest guidelines

Los Angeles, London, New Delhi, Singapore and Washington DC (Jan 6, 2010) If you're one of the millions of headache sufferers around the world, more effective relief might be on the way in years to come. That's because the International Headache Society has just published new research guidelines intended to stimulate more research into headache treatment, and to provide researchers with guidelines to cut health risks associated with treatment. The guidelines appear in the latest issue of Cephalalgia (, now published by SAGE.

Dr Lars Bendtsen and his team from the Clinical Trials Standing Committee of the International Headache Society in Copenhagen, Denmark developed new recommendations on how to improve the quality and safety of the research into treatments for episodic and chronic tension-type headaches. The guidelines will enhance clinical trial safety for patients, and will also allow researchers to determine if older drugs still used to treat tension-type headaches are as effective and safe as they should be.

The last research guidelines for tension-type headache research were published in 1995, but few novel or evidence-based treatment options have become available since that time. Focusing specifically on episodic tension-type headaches (ETTH) and chronic tension-type headaches (CTTH), Bendtsen's goal is to spur new research into the treatment of these commonly occurring headaches. This includes analgesics for episodic headaches as well as preventative treatments for chronic headache sufferers.

Millions of people suffer from ETTH, which can range in frequency from a few times a year to 14 times a month. Many people suffer from CTTH, which can be debilitating. The treatments for these can vary profoundly depending on the severity of the condition.

Over the years, research has found that analgesics - otherwise known as pain-relievers - are usually the most effective way of treating all but the most severe episodic headaches. However, severe episodic headaches and CTTH will often benefit from preventative treatments, which is usually the most effective way of providing lasting relief. Researchers have also found that chronic headache sufferers seldom benefit from analgesics.

Given the many kinds of headache medications available today, and the frequency with which these pain relievers and other treatments are used, new research into tension-related headache treatments will have a great impact on public health. Numerous studies have established that frequent use of analgesics for episodic headaches can increase the risk of side-effects, and can even lead to kidney and liver problems over time. Therefore, identifying more effective treatments for headache sufferers will allow physicians to be more targeted in their choice of drugs. Ultimately, this will translate into a more pain-free life for the tens of millions of people around the world suffering from occasional and chronic tension-type headaches.


Contact: Mithu Lucraft
SAGE Publications UK

Related medicine news :

1. Black gay men, lesbians, have fewer mental disorders than whites, says Mailman School of PH study
2. Fewer adverse cardiac events at one year
3. Hispanics Receive Fewer Surgeries for Vascular Disease
4. Fewer Women Getting Mammograms
5. Fewer Children Outgrowing Allergies to Milk, Eggs
6. Rural Residents Get Fewer Organ Transplants: Study
7. Children who have an active father figure have fewer psychological and behavioral problems
8. Single reader with CAD more efficient, yields fewer false positives, and possibly more sensitive
9. Fewer Steps Per Day Send Disease Markers Up
10. Breast Cancer Radiation Therapy Works in Fewer, But Higher Doses
11. Overweight kids have fewer cavities, new study shows
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... ... eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, ... Medicine tests directly from their electronic medical record (EMR) without the need for ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... of workshops to discuss bioavailability and the need to integrate dose form selection ... in collaboration with OBN, the membership organization supporting and bringing together the UK’s ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... PRMA Plastic ... November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! , ... wake up every day excited to rebuild lives and it’s an honor to have ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film Studios brings Final ... ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, ... giving users limitless opportunities to stylize and create designs quickly and easily, all ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of the ... to improve system efficiency and reliability. , The new Q-Suite 6 platform is based ... system avoids locking itself into a specific piece of software for many key components ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Therapeutic Drug Monitoring (TDM) Market: ... Intelligence, Emerging Opportunities"  report to their ... has announced the addition of the  ...
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
Breaking Medicine Technology: